Tags : PF-05280586

Pfizer Reports Results of PF-05280586 (rituximab biosimilar) in REFLECTIONS B328-06

Vartika Singh December 3, 2018

Shots: The REFLECTIONS B328-06 study involves assessing of PF-05280586 vs Rituxan/MabThera (rituximab) in patients with 1L CD20-positive, low tumor burden, follicular lymphoma evaluating its efficacy, safety and immunogenicity, PK and […]readmore

Tags : PF-05280586

Pfizer Reports Results of PF-05280586 (rituximab biosimilar) in REFLECTIONS B328-06

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : PF-05280586

Pfizer Reports Results of PF-05280586 (rituximab biosimilar) in REFLECTIONS B328-06

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company